Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Although in vitro observations suggest that cross-presentation of antigens is mediated primarily by CD8alpha+ dendritic cells, in vivo analysis has been hampered by the lack of systems that selectively eliminate this cell lineage. We show that deletion of the transcription factor Batf3 ablated development of CD8alpha+ dendritic cells, allowing us to examine their role in immunity in vivo. Dendritic cells from Batf3-/- mice were defective in cross-presentation, and Batf3-/- mice lacked virus-specific CD8+ T cell responses to West Nile virus. Importantly, rejection of highly immunogenic syngeneic tumors was impaired in Batf3-/- mice. These results suggest an important role for CD8alpha+ dendritic cells and cross-presentation in responses to viruses and in tumor rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“appears essential for T cell-driven antitumor immunity (Hildner et al., 2008)”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
In the citing paper
“Both DC1s and DC2s expressed the DC markers Batf3, Flt3, H2-Dmb2 and Zbtb46 (Meredith et al., 2012; Hildner et al., 2008;); DC1 expressed Fscn1 and Ly 75 (DEC-205) whereas DC2s expressed CD209a (DC- SIGN), Mgl2 (CD301b) and Cd24a (Figure 2B and Figure S2B).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citationJung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Barnden, M. J., Allison, J., Heath, W. R., & Carbone, F. R. (1998) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1998.00709.x · Cited by 1,489
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,328
Steady-state and inflammatory dendritic-cell development
Shortman, K., & Naik, S. H. (2007) · Nature Reviews Immunology · doi:10.1038/nri1996 · Cited by 1,190
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Bevan, M. J. (1976) · The Journal of experimental medicine · doi:10.1084/jem.143.5.1283 · Cited by 956
Toll-like receptor 3 promotes cross-priming to virus-infected cells
Schulz, O., Diebold, S. S., Chen, M., Näslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y.-T., Flavell, R. A., Liljeström, P., & Reis e Sousa, C. (2005) · Nature · doi:10.1038/nature03326 · Cited by 921
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Cited by
Items 401–500 of 1,008
Complex interactions of transcription factors in mediating cytokine biology in T cells
Li, P., Spolski, R., Liao, W., & Leonard, W. J. (2014) · Immunological Reviews · doi:10.1111/imr.12199 · Cited by 119
“However, BATF and BATF3, respectively, can have positive transcriptional effects on Th cell differentiation and CD8a lymphoid-resident dendritic cells (52, 158).”
BackgroundEdelson, B. T., Bradstreet, T. R., KC, W., Hildner, K., Herzog, J. W., Sim, J., Russell, J. H., Murphy, T. L., Unanue, E. R., & Murphy, K. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025660 · Cited by 119
“unexpected population of DEC205CD8a cDCs that were eliminated in the spleen and SDLNs of 129S6/SvEv Batf3 mice [16,27] (Fig.”
BackgroundLangerhans cells are generated by two distinct PU.1-dependent transcriptional networks
Chopin, M., Seillet, C., Chevrier, S., Wu, L., Wang, H., Morse, H. C., Belz, G. T., & Nutt, S. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130930 · Cited by 119
“2 E; Hildner et al., 2008; Edelson et al., 2010; Crozat et al., 2011; Bachem et al., 2012).”
Ruane, D., Chorny, A., Lee, H., Faith, J., Pandey, G., Shan, M., Simchoni, N., Rahman, A., Garg, A., Weinstein, E. G., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20150567 · Cited by 118
“To assess the in vivo contribution of LDCs to IgA induction , we immunized Batf3 −/− mice lacking CD103 + DCs (Hildner et al., 2008) and WT mice with CT and serially examined the induction of IgA + B cells in the lung and MedLN.”
Sharma, M. D., Rodriguez, P. C., Koehn, B. H., Baban, B., Cui, Y., Guo, G., Shimoda, M., Pacholczyk, R., Shi, H., Lee, E.-J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.014 · Cited by 119
“Batf3-deficient mice lack critical antigen-presenting activity required for anti-tumor immunity (Hildner et al., 2008).”
BackgroundResultInfluentialDirect reprogramming of fibroblasts into antigen-presenting dendritic cells
Rosa, F. A., Pires, C. F., Kurochkin, I., Ferreira, A. G., Gomes, A., Palma, L. G., Shaiv, K., Solanas, L., Azenha, C. D. J., Papatsenko, D. A., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aau4292 · Cited by 132
FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
Yan, J., Zhao, Q., Gabrusiewicz, K. R., Kong, L.-Y., Xia, X., Wang, J., Ott, M., Xu, J., Davis, R. E., Huo, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08271-x · Cited by 125
Gut-resident CX3CR1 hi macrophages induce tertiary lymphoid structures and IgA response in situ
Koscsó, B., Kurapati, S., Rodrigues, R. R., Nedjic, J., Gowda, K., Shin, C., Soni, C., Ashraf, A. Z., Purushothaman, I., Palisoc, M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aax0062 · Cited by 118
“Because Batf3 and Notch2 control cDC1 and cDC2 development systemically (35, 36, 39), cDC1 and cDC2 from the mucosa and MLNs could be responsible for the induction of systemic Salmonella-specific antibody responses.”
BackgroundResultSummers, K. M., Bush, S. J., & Hume, D. A. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000859 · Cited by 117
Ablation of cDC2 development by triple mutations within the Zeb2 enhancer
Liu, T., Kim, S. K., Desai, P., Kim, D., Huang, X., Ferris, S. T., Wu, R., Ou, F., Egawa, T., Dyken, S. J. V., et al. (2022) · Nature · doi:10.1038/s41586-022-04866-z · Cited by 127
Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations
Lee, K.-W., Yam, J. W. P., & Mao, X. (2023) · Cells · doi:10.3390/cells12172147 · Cited by 117
Hartung, E., Becker, M., Bachem, A., Reeg, N., Jaekel, A., Hutloff, A., Weber, H., Weise, C., Giesecke‐Thiel, C., Henn, V., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401903 · Cited by 121
Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction
Desch, A. N., Gibbings, S. L., Clambey, E. T., Janssen, W. J., Slansky, J. E., Kedl, R. M., Henson, P. M., & Jakubzick, C. (2014) · Nature Communications · doi:10.1038/ncomms5674 · Cited by 118
Riedhammer, C., & Weissert, R. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00322 · Cited by 117
“The epitopes of an antigen presented by B cells might therefore be different from those presented by thymic epithelial and DCs, including the possibility that T cells specific for epitopes presented by B cells might escape central tolerance induction more easily.”
BackgroundInfluentialEverts, B., Tussiwand, R., Dreesen, L., Fairfax, K. C., Huang, S. C.-C., Smith, A. M., O’Neill, C. M., Lam, W. Y., Edelson, B. T., Urban, J. F., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20150235 · Cited by 117
“…Batf3−/− mice have demonstrated that CD8α+ and CD103+ DCs have superior Ag cross-presenting capabilities and as a result play a critical role in antiviral and antitumor immunity through the generation of cytotoxic T cell responses (Hildner et al., 2008; Fuertes et al., 2011; Zelenay et al., 2012).”
InfluentialCross-Presentation in Mouse and Human Dendritic Cells
Segura, É., & Amigorena, S. (2015) · Advances in immunology · doi:10.1016/bs.ai.2015.03.002 · Cited by 143
Kidney dendritic cells: fundamental biology and functional roles in health and disease
Kurts, C., Ginhoux, F., & Panzer, U. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0272-y · Cited by 126
Lurje, I., Hammerich, L., & Tacke, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197378 · Cited by 126
The challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., Vierling, J. M., Adams, D., Alpini, G., Banales, J. M., Beuers, U., Björnsson, E., Bowlus, C., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102328 · Cited by 114
Fu, C., Peng, P., Loschko, J., Li, F., Pham, P., Cui, W., Lee, K. P., Krug, A., & Jiang, A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002345117 · Cited by 127
“Among cDCs, Batf3-dependent cDC1s are recognized as the superior APCs in cross-presenting exogenous antigens including tumor antigens to prime CD8 T cells (75, 92, 93).”
BackgroundMethodOvercoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
Dendritic cells and cancer immunotherapy
Radford, K. J., Tullett, K. M., & Lahoud, M. H. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.005 · Cited by 121
Baptista, A. P., Gola, A., Huang, Y., Milanez‐Almeida, P., Torabi‐Parizi, P., Urban, J. F., Shapiro, V. S., Gerner, M. Y., & Germain, R. N. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.001 · Cited by 122
DC-Derived Exosomes for Cancer Immunotherapy
Yao, Y., Fu, C., Zhou, L., Mi, Q., & Jiang, A. (2021) · Cancers · doi:10.3390/cancers13153667 · Cited by 121
“cDC1 cells depend on interferon regulatory factor 8 (IRF8) and basic leucine zipper transcriptional factor ATF-like 3 (Batf3) for their development, and are specialized in presenting internalized antigens bound to MHCI to CD8 T cells in a process termed cross-presentation [13,14].”
BackgroundDevelopment, Diversity, and Function of Dendritic Cells in Mouse and Human
Anderson, D. A., MURPHY, K. M. M., & Briseño, C. G. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028613 · Cited by 125
“…Nfil3, Id2, and Bcl6 are all associated with the loss of cDC1s in lymphoid and nonlymphoid tissues (Schiavoni et al. 2002; Aliberti et al. 2003; Hacker et al. 2003; Kusunoki et al. 2003; Hildner et al. 2008; Edelson et al. 2010; Kashiwada et al. 2011; Ohtsuka et al. 2011; Watchmaker et al. 2014).”
BackgroundMethodInfluentialBlocking IDO activity to enhance anti-tumor immunity
Munn, D. (2012) · Frontiers in Bioscience · doi:10.2741/414 · Cited by 114
“IDO and tolerance to tumors Studies suggest that resting T cells initially become aware of tumor antigens primarily through crosspresentation on host antigen-presenting cells (8, 79, 80).”
BackgroundAntigen expression determines adenoviral vaccine potency independent of IFN and STING signaling
Quinn, K. M., Zak, D. E., Costa, A. D. S., Yamamoto, A., Kastenmüller, K., Hill, B. J., Lynn, G. M., Darrah, P. A., Lindsay, R. W. B., Wang, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78280 · Cited by 113
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Chen, Q., Sun, T., & Jiang, C. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00622-6 · Cited by 124
Schlitzer, A., Loschko, J., Mair, K., Vogelmann, R., Henkel, L., Einwächter, H., Schiemann, M., Niess, J.-H., Reindl, W., & Krug, A. (2011) · Blood · doi:10.1182/blood-2010-12-326678 · Cited by 113
Zhou, Y., Slone, N., Chrisikos, T. T., Kyrysyuk, O., Babcock, R. L., Medik, Y. B., Li, H. S., Kleinerman, E. S., & Watowich, S. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000474 · Cited by 112
Mildner, A., Chapnik, E., Manor, O., Yona, S., Kim, K.-W., Aychek, T., Varol, D., Beck, G., Itzhaki, Z. B., Feldmesser, E., et al. (2013) · Blood · doi:10.1182/blood-2012-07-445999 · Cited by 112
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
Drakes, M. L., & Stiff, P. J. (2018) · Cancers · doi:10.3390/cancers10090302 · Cited by 121
“The lack of conventional DC as in Batf3 −/− mice abolishes the rejection of immunogenic tumors, the response to adoptive T cell therapy, and to immune checkpoint blockade [114,115,119,120].”
BackgroundContreras, V., Urien, C., Guiton, R., Alexandre, Y. O., Manh, T. V., Andrieu, T., Crozat, K., Jouneau, L., Bertho, N., Epardaud, M., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000824 · Cited by 124
“In addition, deletion of the basic leucine zipper transcription factor ATF-like 3 (BATF3) abrogated the development of both the dermal CD103 DCs and the LT CD8a DCs (20, 21).”
BackgroundMouse pancreatic islet macrophages use locally released ATP to monitor beta cell activity
Weitz, J., Makhmutova, M., Almaça, J., Stertmann, J., Aamodt, K. I., Briššová, M., Speier, S., Rodriguez‐Diaz, R., & Caicedo, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4416-y · Cited by 117
Ding, Y., Guo, Z., Liu, Y., Li, X., Zhang, Q., Xu, X., Gu, Y., Zhang, Y., Zhao, D., & Cao, X. (2016) · Nature Immunology · doi:10.1038/ni.3535 · Cited by 114
CD8α+ DCs can be induced in the absence of transcription factors Id2, Nfil3, and Batf3
Seillet, C., Jackson, J. T., Markey, K. A., Brady, H. J. M., Hill, G. R., MacDonald, K. P. A., Nutt, S. L., & Belz, G. T. (2013) · Blood · doi:10.1182/blood-2012-07-445650 · Cited by 109
Coquet, J. M., Middendorp, S., Horst, G., Kind, J., Veraar, E. A. M., Xiao, Y., Jacobs, H., & Borst, J. G. (2012) · Immunity · doi:10.1016/j.immuni.2012.09.009 · Cited by 123
“However, transcriptional regulation by the JNK pathway is much more complex. c-Jun belongs to a family of basic leucine zipper transcription factors that can heterodimerize with members of the related Crem and Atf family, to which Batf, Batf-3, Atf-3, and Crem belong.”
MethodInfluentialDawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy
Nakamura, T., & Harashima, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.003 · Cited by 111
The aged tumor microenvironment limits T cell control of cancer
Chen, C.-Y., Jaiswal, S., Martínez, D., Yerinde, C., Ji, K. Y., Miranda, V., Fung, M. E., Weiss, S. A., Zschummel, M., Taguchi, K., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01828-7 · Cited by 128
Arora, P., Baena, A., Yu, K. O. A., Saini, N. K., Kharkwal, S. S., Goldberg, M. F., Kunnath-Velayudhan, S., Carreño, L. J., Venkataswamy, M. M., Kim, J., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.004 · Cited by 114
“These mice lack CD8a+ DCs and have few if any other immunological defects (Hildner et al., 2008).”
BackgroundMechanisms of Tumor Cell–Intrinsic Immune Evasion
Spranger, S., & Gajewski, T. F. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050606 · Cited by 108
“This observation is consistent with the critical importance of Batf3 DCs in the cross-presentation of tumor-derived antigens to CD8+ T cells in vivo (Engelhardt et al. 2012, Fuertes et al. 2011, Hildner et al. 2008).”
ResultTumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity
Crittenden, M. R., Zebertavage, L., Kramer, G. F., Bambina, S., Friedman, D. J., Troesch, V., Blair, T. C., Baird, J. R., Alice, A. F., & Gough, M. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-25482-w · Cited by 110
Wang, S., Xiong, Y., Zhang, Q., Su, D., Yu, C., Cao, Y., Pan, Y., Lu, Q., Zuo, Y., & Yang, L. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa311 · Cited by 140
Radtke, A. J., Kastenmüller, W., Espinosa, D. A., Gerner, M. Y., Tse, S.-W., Sinnis, P., Germain, R. N., Zavala, F. P., & Cockburn, I. A. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004637 · Cited by 106
“LN-resident CD8α DCs are necessary for CD8 T cell priming Given the enrichment of CD8α DCs in OT-1 clusters at time points corresponding to CD8 T cell activation, we next examined the contribution of these DCs to sporozoite-specific T cell activation in Batf3 mice that possess substantial defects in the numbers of CD8…”
Dai, L., Cui, X., Zhang, X., Cheng, L., Liu, Y., Yang, Y., Fan, P., Wang, Q., Lin, Y., Zhang, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11996 · Cited by 107
RetractedMechanisms of Immune Tolerance in Leukemia and Lymphoma
Curran, E. K., Godfrey, J. K., & Kline, J. P. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.04.004 · Cited by 128
Vaccine adjuvants to engage the cross-presentation pathway
Lee, W., & Suresh, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940047 · Cited by 114
“Further, mice deficient in WDFY Family Member 4 (WDFY4) or Basic Leucine Zipper ATF-Like Transcription Factor 3 (BATF3) exhibit defects in their ability to prime virus-specific CD8+ T cells in vivo or to induce tumor rejection, suggesting that cDC1 is the major cross-presenting DC subset in mice in vivo (26, 27).”
BackgroundPinto, A. K., Daffis, S., Brien, J. D., Gainey, M. D., Yokoyama, W. M., Sheehan, K. C. F., Murphy, K. M., Schreiber, R. D., & Diamond, M. S. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002407 · Cited by 107
“To evaluate whether the temporal effect of type I IFN signaling on CD8 T cell responses occurred in mice with impaired cross-presentation capacity, we utilized BATF3 mice, which lack CD8-a and CD103 dendritic cells [18,42].”
BackgroundMethodResultInfluentialcGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors
Li, G., Zhao, X., Zheng, Z., Zhang, H., Wu, Y., Shen, Y., & Chen, Q. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05191-6 · Cited by 121
Molecular mechanisms involved in dendritic cell dysfunction in cancer
Tang, M., Diao, J., & Cattral, M. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2317-8 · Cited by 113
“Pre-DCs differentiate into two main cDC subpopulations: (1) lymphoid-tissue resident CD8a CD11b cDC and tissue CD103 CD11b cDCs (cDC1), which specialize in cross presentation of exogenous antigens on MHC-I molecules to CD8 T cells [32]; and (2) CD11b cDC (cDC2), which have a dominant role in presenting endogenous anti…”
Dendritic Cell Subsets in Intestinal Immunity and Inflammation
Sun, T., Nguyen, A., & Gommerman, J. L. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900710 · Cited by 105
GM‐CSF increases cross‐presentation and CD103 expression by mouse CD8+ spleen dendritic cells
Zhan, Y., Carrington, E. M., van Nieuwenhuijze, A., Bedoui, S., Seah, S., Xu, Y., Wang, N., Mintern, J. D., Villadangos, J. A., Wicks, I. P., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201141540 · Cited by 103
Ding, Y., Wilkinson, A., Idris, A., Fancke, B., O’Keeffe, M. A., Khalil, D., Ju, X., Lahoud, M. H., Caminschi, I., Shortman, K., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302391 · Cited by 104
Transcriptional Control of Dendritic Cell Development
MURPHY, K. M. M. (2013) · Advances in immunology · doi:10.1016/b978-0-12-417028-5.00009-0 · Cited by 112
Regulated IRE1-dependent mRNA decay sets the threshold for dendritic cell survival
Tavernier, S. J., Osorio, F., Vandersarren, L., Vetters, J., Vanlangenakker, N., Isterdael, G. V., Vergote, K., Rycke, R. M. D., Parthoens, E., van de Laar, L., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3518 · Cited by 122
Chopin, M., Lun, A. T., Zhan, Y., Schreuder, J., Coughlan, H., D’Amico, A., Mielke, L. A., Almeida, F. F., Kueh, A. J., Dickins, R. A., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.11.010 · Cited by 104
Calmeiro, J., Carrascal, M. A., Tavares, A. R., Ferreira, D. A., Gomes, C. M. F., Falcão, A. C., Cruz, M. T., & Neves, B. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020158 · Cited by 116
Disentangling the complexity of the skin dendritic cell network
Henri, S., Guilliams, M., Poulin, L. F., Tamoutounour, S., Ardouin, L., Dalod, M., & MALISSEN, B. (2010) · Immunology and Cell Biology · doi:10.1038/icb.2010.34 · Cited by 108
E4BP4: an unexpected player in the immune response
Male, V. H., Nisoli, I., Gascoyne, D. M., & Brady, H. J. M. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.10.002 · Cited by 102
Torti, N., Walton, S. M., MURPHY, K. M. M., & Oxenius, A. (2011) · European Journal of Immunology · doi:10.1002/eji.201041075 · Cited by 102
Beta Interferon Controls West Nile Virus Infection and Pathogenesis in Mice
Lazear, H. M., Pinto, A. K., Vogt, M. R., Gale, M., & Diamond, M. S. (2011) · Journal of Virology · doi:10.1128/jvi.00396-11 · Cited by 101
“This observation is noteworthy, because type I IFN facilitates CD8 T cell activation and maturation through a cross-presentation mechanism, and optimal induction of WNV-specific CD8 T cells requires CD8 dendritic cells, the primary cell type that mediates antigen cross-presentation in vivo (32).”
BackgroundSwiecki, M. K., Wang, Y., Gilfillan, S., & Colonna, M. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003728 · Cited by 113
“Next, we measured serum IFN-a levels and CD8 T cell responses in Batf3 mice, which have a defect in CD8a DC numbers [41,42], after systemic HSV-1 infection.”
MethodAli, O. A., Verbeke, C., Johnson, C., Sands, R. W., Lewin, S. A., White, D., Doherty, E., Dranoff, G., & Mooney, D. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0777 · Cited by 101
“Batf3 / transgenic mice were used in these experiments, as they lack CD8(þ) DCs, without exhibiting abnormalities in other hematopoietic cell types or tissue architecture (20).”
Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion
DeVito, N. C., Plebanek, M. P., Theivanthiran, B., & Hanks, B. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02876 · Cited by 100
Cellular cytotoxicity is a form of immunogenic cell death
Minute, L., Teijeira, Á., Sánchez-Paulete, A. R., Ochoa, M. C., Álvarez, M., Otano, I., Etxeberría, I., Bolaños, E., Azpilikueta, A., Garasa, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000325 · Cited by 116
Programme of self-reactive innate-like T cell-mediated cancer immunity
Chou, C., Zhang, X., Krishna, C., Nixon, B. G., Dadi, S., Capistrano, K. J., Kansler, E. R., Steele, M., Han, J., Shyu, A., et al. (2022) · Nature · doi:10.1038/s41586-022-04632-1 · Cited by 110
DNGR-1 in dendritic cells limits tissue damage by dampening neutrophil recruitment
del Fresno, C., Saz-Leal, P., Enamorado, M., Wculek, S. K., Martínez-Cano, S., Blanco-Menéndez, N., Schulz, O., Gallizioli, M., Miró-Mur, F., Cano, E., et al. (2018) · Science · doi:10.1126/science.aan8423 · Cited by 100
The Role of Type-2 Conventional Dendritic Cells in the Regulation of Tumor Immunity
Saito, Y., Komori, S., Kotani, T., Murata, Y., & Matozaki, T. (2022) · Cancers · doi:10.3390/cancers14081976 · Cited by 117
“The development of mouse cDC1s is dependent on the transcriptional factors IRF8 and BATF3 [26,27].”
BackgroundDupont, C. D., Christian, D. A., Selleck, E. M., Pepper, M., Leney-Greene, M. A., Pritchard, G. H., Koshy, A. A., Wagage, S., Reuter, M. A., Sibley, L. D., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004047 · Cited by 113
“Furthermore, when Flt3L mice (which have global defects in numbers of dendritic cells [51]) or Batf3 mice (which have a defect in numbers of CD8a dendritic cells [52]) were challenged with cpsII-OVA, both mice displayed marked defects in tetramer-specific and total CD4 and CD8 T cell responses”
BackgroundPerez, O. A., Yeung, S. T., Vera-Licona, P., Romagnoli, P. A., Samji, T., Ural, B. B., Maher, L., Tanaka, M., & Khanna, K. M. (2017) · Science Immunology · doi:10.1126/sciimmunol.aah5520 · Cited by 99
“Currently, it is understood that, after initial deposition in the spleen, Lm is transported from the MZs to the T cell zones by CD8 + DCs, where Lm further replicates ( 14 , 29 ).”
Newcastle Disease Virus at the Forefront of Cancer Immunotherapy
Burman, B., Pesci, G., & Zamarin, D. (2020) · Cancers · doi:10.3390/cancers12123552 · Cited by 114
“Recognition of PAMPs and DAMPs by PRRs leads to the activation of transcription factors including IFN regulatory factor (IRF)3, IRF7, and nuclear factor kappa B via the adaptors interferon β stimulator-1 and stimulator of interferon genes (STING) [44].”
BackgroundInfluentialSmed-Sörensen, A., Chalouni, C., Chatterjee, B., Cohn, L., Blattmann, P., Nakamura, N., Delamarre, L., & Mellman, I. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002572 · Cited by 99
“[15].”
BackgroundGuo, Z., Li, Y., Zhang, D., & Ma, J. (2017) · Oncotarget · doi:10.18632/oncotarget.21125 · Cited by 110
“As professional antigen-presenting cells, cDCs play a critical role in inducing and maintaining antitumor cytotoxic T cell (CTLs) [32]; specifically, a subpopulation of Batf3-dependent CD103+ (CD141+ in human) cDCs has been defined to be capable of cross-priming antitumor CTLs within lymph nodes and restimulating CTLs…”
BackgroundGranja, A. G., Leal, E., Pignatelli, J., Castro, R., Abós, B., Kato, G., Fischer, U., & Tafalla, C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500322 · Cited by 104
“The functionality of these two DC subtypes is dependent on similar transcription factors (17), and they are derived exclusively from pre-DCs under the control of Flt3 ligand, IFN regulatory protein (IRF)8 (18, 19), and Batf3 (20, 21).”
BackgroundInfluentialCauwels, A., Van Lint, S., Paul, F., Garcin, G., De Koker, S., Van Parys, A., Wueest, T., Gerlo, S., Van der Heyden, J., Bordat, Y., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1980 · Cited by 97
Lymph node conduits transport virions for rapid T cell activation
Reynoso, G. V., Weisberg, A. S., Shannon, J. P., McManus, D. T., Shores, L., Americo, J. L., Stan, R. V., Yewdell, J. W., & Hickman, H. D. (2019) · Nature Immunology · doi:10.1038/s41590-019-0342-0 · Cited by 97
Lo, J. A., Kawakubo, M., Juneja, V. R., Su, M. Y., Erlich, T. H., LaFleur, M. W., Kemeny, L. V., Rashid, M., Malehmir, M., Rabi, S. A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd8636 · Cited by 97
The ReNAissanCe of mRNA-based cancer therapy
Van Lint, S., Renmans, D., Broos, K., Dewitte, H., Lentacker, I., Heirman, C., Breckpot, K., & Thielemans, K. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.957685 · Cited by 95
Decoding immunogenic cell death from a dendritic cell perspective
Janssens, S., Rennen, S., & Agostinis, P. (2023) · Immunological Reviews · doi:10.1111/imr.13301 · Cited by 114
Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice
Kerschen, E., Hernandez, I., Zogg, M., Jia, S., Hessner, M. J., Fernandez, J. A., Griffin, J. H., Huettner, C. S., Castellino, F. J., & Weiler, H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42629 · Cited by 94
Kim, E. H., Woodruff, M. C., Grigoryan, L., Maier, B. B., Lee, S. H., Mandal, P., Cortese, M., Natrajan, M. S., Ravindran, R., Ma, H., et al. (2020) · eLife · doi:10.7554/elife.52687 · Cited by 103
“With respect to the cell types involved in Ag cross-presentation to CD8 T cells, it is known that CD8a+ DCs are the key mediators of this process (den Haan et al., 2000; Hildner et al., 2008).”
BackgroundDavey, G. M., Wojtasiak, M., Proietto, A. I., Carbone, F. R., Heath, W. R., & Bedoui, S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903013 · Cited by 94
“A precursor-product relationship has recently been proposed for CD8a DCs and CD103 DCs (22).”
BackgroundWalton, S. M., Mandaric, S., Torti, N., Zimmermann, A., Hengel, H., & Oxenius, A. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002214 · Cited by 93
“). It is likely that these non-infected bystander APCs are presenting MCMV-derived antigens to MCMV-specific T cells. As these bystander cells were clearly not directly infected since they lacked GFP expression, these cells would have to present MCMV antigens from an exogenous source. It is conceivable that MHC class…”
Murine CD103+ dendritic cells protect against steatosis progression towards steatohepatitis
Heier, E.-C., Meier, A., Julich-Haertel, H., Djudjaj, S., Rau, M., Tschernig, T., Geier, A., Boor, P., Lammert, F., & Lukacs-Kornek, V. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.008 · Cited by 94
Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates
Robert, J. (2010) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2010.05.011 · Cited by 100
Ruckwardt, T. J., Malloy, A. M. W., Morabito, K. M., & Graham, B. S. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003934 · Cited by 93
“Batf3-deficient mice, lacking both tissue-resident CD103+ DCs and CD8a+ DCs, show a marked reduction in CD8+ T cell responses [12,13], and CD103+ DCs have also been shown to have the unique capability”
BackgroundChemokines control naive CD8+ T cell selection of optimal lymph node antigen presenting cells
Hickman, H. D., Li, L., Reynoso, G. V., Rubin, E. J., Skon, C. N., Mays, J. W., Gibbs, J., Schwartz, O., Bennink, J. R., & Yewdell, J. W. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102545 · Cited by 92
“In mouse LNs, conventional DCs include the CD8+ and CD11b+ subgroups, the latter sub divided based on CD4 expression (Vremec et al., 2000; Allan et al., 2003; Belz et al., 2004; Hildner et al., 2008).”
BackgroundTzelepis, F., Verway, M., Daoud, J., Gillard, J., Hassani-Ardakani, K., Dunn, J., Downey, J., Gentile, M. E., Jaworska, J., Sanchez, A. M. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77014 · Cited by 92
“To study the role of annexin1 in MHC-I–restricted crosspresentation of cell-associated antigen, purified splenic DCWT or DCAnxa1–/– were incubated with either OVA-loaded or unloaded apoptotic cells from β2-microglobulin deficient mice (B2m–/–) and cocultured with CFSE-labeled OT-I T cells (39).”
Type I IFN activating type I dendritic cells for antitumor immunity
Liang, Y., Hannan, R., & Fu, Y.-X. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2564 · Cited by 91
“cDC1s that crossprime CD8þ T-cell responses are involved in spontaneously rejecting tumor immunity (7).”
BackgroundZhang, H., Madi, A., Yosef, N., Chihara, N., Awasthi, A., Pot, C., Lambden, C., Srivastava, A., Burkett, P. R., Nyman, J., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108433 · Cited by 91
DNA methylation dynamics during ex vivo differentiation and maturation of human dendritic cells
Zhang, X., Ulm, A., Somineni, R. P., Oh, S., Weirauch, M. T., Zhang, H.-X., Chen, X., Lehn, M. A., Janssen, E. M., & Ji, H. (2014) · Epigenetics & Chromatin · doi:10.1186/1756-8935-7-21 · Cited by 98
“In addition, BATF3 binds to JUN and is required for the normal development of CD8α cDCs in mouse models and BDCA3 DCs in humans [27-29].”
Nucleic Acid Sensors as Therapeutic Targets for Human Disease
McWhirter, S. M., & Jefferies, C. A. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.004 · Cited by 91
pDC-like cells are pre-DC2 and require KLF4 to control homeostatic CD4 T cells
Rodrigues, P. F., Kouklas, A., Cvijetic, G., Bouladoux, N. J., Mitrovic, M., Desai, J. V., Lima-Junior, D. S., Lionakis, M. S., Belkaid, Y., Ivánek, R., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add4132 · Cited by 94
Targeting Dendritic Cells in vivo for Cancer Therapy
Caminschi, I., Maraskovsky, E., & Heath, W. R. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00013 · Cited by 91
“However, cross-presentation upon targeting Clec9A was significantly inhibited in BatF3−/− re-iterating the important role of CD8+ DC in activating CD8 T cells in vivo (Caminschi et al., 2011).”
BackgroundInfluentialRegulation of Antigen Export to the Cytosol During Cross-Presentation
Gros, M., & Amigorena, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00041 · Cited by 90
Brophy, P. D., Rasmussen, M. B., Parida, M., Bonde, G., Darbro, B. W., Hong, X., Clarke, J. C., Peterson, K. A., Denegre, J. M., Schneider, M., et al. (2017) · Genetics · doi:10.1534/genetics.117.1125 · Cited by 99
“GREB1L expression pattern supports its role in kidney morphogenesis Transcriptome analysis shows that GREB1L is expressed in a variety of tissues (www.genecards.org), with particularly high expression in brain, kidney, and ovary (GEO accession number GSM35549, profile GDS3052; Hildner et al. 2008).”
BackgroundMartinvalet, D. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0237-7 · Cited by 89
Notch2-dependent DC2s mediate splenic germinal center responses
Briseño, C. G., Satpathy, A. T., Davidson, J. T., Ferris, S. T., Durai, V., Bagadia, P., O’Connor, K., Theisen, D. J., Murphy, T. L., & MURPHY, K. M. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809925115 · Cited by 100
“The generation of Zbtb46 and Batf3mice has been described previously (34, 36).”
Immune correlates of tuberculosis disease and risk translate across species
Ahmed, M., Thirunavukkarasu, S., Rosa, B. A., Thomas, K. A., Das, S., Rangel-Moreno, J., Lu, L., Mehra, S., Mbandi, S. K., Thackray, L. B., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay0233 · Cited by 89
Self-citationHost Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance
Johnson, T. S., & Munn, D. H. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.689405 · Cited by 107
“Despite failing to respond, resting T cells are exposed to tumor antigens via cross-presentation on host antigenpresenting cells (Huang et al., 1994; Sotomayor et al., 2001; Hildner et al., 2008).”
Metadata
- Authors
- Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., Schreiber, R. D., Murphy, T. L., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
- Corresponding author
- Murphy, Kenneth M.
- ORCID
- Venue
- Science
- Published
- 2008-11-14
- Volume
- 322
- Issue
- 5904
- Pages
- 1097-1100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2756611
- OpenAlex
- W2046505430
- Cited by
- 2,081
- References
- 29
- Citations by year
- 2026: 117 · 2025: 150 · 2024: 142 · 2023: 129 · 2022: 161 · 2021: 167 · 2020: 182 · 2019: 129 · 2018: 109 · 2017: 133 · 2016: 115 · 2015: 105 · 2014: 92 · 2013: 89 · 2012: 90
- FWCI
- 23.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- Batf3, CD8α+ dendritic cells, cross-presentation, West Nile virus, tumor rejection, dendritic cell development, transcription factors, antitumor immunity
- MeSH terms
- Animals, Antibodies, Viral, Cytotoxicity, Immunologic, Dendritic Cells, Female, Fibrosarcoma, Lymphocyte Activation, Male, Mice, Inbred C57BL, Repressor Proteins, Spleen, T-Lymphocytes, Cytotoxic, West Nile Fever, West Nile virus, CD4-Positive T-Lymphocytes, CD8 Antigens, Adoptive Transfer, Cross-Priming, Basic-Leucine Zipper Transcription Factors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.